![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GBP4 |
Gene summary for GBP4 |
![]() |
Gene information | Species | Human | Gene symbol | GBP4 | Gene ID | 115361 |
Gene name | guanylate binding protein 4 | |
Gene Alias | Mpa2 | |
Cytomap | 1p22.2 | |
Gene Type | protein-coding | GO ID | GO:0001562 | UniProtAcc | Q96PP9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
115361 | GBP4 | CA_HPV_1 | Human | Cervix | CC | 1.32e-14 | 5.39e-01 | 0.0264 |
115361 | GBP4 | CCI_2 | Human | Cervix | CC | 6.37e-03 | 5.84e-01 | 0.5249 |
115361 | GBP4 | Tumor | Human | Cervix | CC | 9.52e-10 | 2.98e-01 | 0.1241 |
115361 | GBP4 | sample1 | Human | Cervix | CC | 4.01e-07 | 5.22e-01 | 0.0959 |
115361 | GBP4 | sample3 | Human | Cervix | CC | 3.88e-15 | 3.18e-01 | 0.1387 |
115361 | GBP4 | T1 | Human | Cervix | CC | 2.84e-09 | 4.28e-01 | 0.0918 |
115361 | GBP4 | T3 | Human | Cervix | CC | 1.02e-10 | 2.90e-01 | 0.1389 |
115361 | GBP4 | LZE4T | Human | Esophagus | ESCC | 2.37e-02 | 8.88e-02 | 0.0811 |
115361 | GBP4 | LZE8T | Human | Esophagus | ESCC | 2.72e-03 | 1.68e-01 | 0.067 |
115361 | GBP4 | LZE20T | Human | Esophagus | ESCC | 2.95e-06 | 2.29e-01 | 0.0662 |
115361 | GBP4 | LZE24T | Human | Esophagus | ESCC | 6.29e-04 | 1.21e-01 | 0.0596 |
115361 | GBP4 | LZE6T | Human | Esophagus | ESCC | 9.61e-05 | 2.14e-01 | 0.0845 |
115361 | GBP4 | P2T-E | Human | Esophagus | ESCC | 8.27e-11 | 3.79e-01 | 0.1177 |
115361 | GBP4 | P8T-E | Human | Esophagus | ESCC | 2.32e-08 | 3.23e-01 | 0.0889 |
115361 | GBP4 | P9T-E | Human | Esophagus | ESCC | 8.16e-12 | 4.20e-01 | 0.1131 |
115361 | GBP4 | P11T-E | Human | Esophagus | ESCC | 6.27e-12 | 5.86e-01 | 0.1426 |
115361 | GBP4 | P15T-E | Human | Esophagus | ESCC | 3.26e-02 | 1.59e-01 | 0.1149 |
115361 | GBP4 | P17T-E | Human | Esophagus | ESCC | 3.52e-10 | 4.48e-01 | 0.1278 |
115361 | GBP4 | P20T-E | Human | Esophagus | ESCC | 1.51e-02 | 1.75e-01 | 0.1124 |
115361 | GBP4 | P23T-E | Human | Esophagus | ESCC | 2.24e-15 | 3.22e-01 | 0.108 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00343415 | Cervix | CC | response to interferon-gamma | 30/2311 | 141/18723 | 1.88e-03 | 1.39e-02 | 30 |
GO:00713463 | Cervix | CC | cellular response to interferon-gamma | 25/2311 | 118/18723 | 4.54e-03 | 2.75e-02 | 25 |
GO:00343418 | Esophagus | ESCC | response to interferon-gamma | 86/8552 | 141/18723 | 1.74e-04 | 1.14e-03 | 86 |
GO:00713466 | Esophagus | ESCC | cellular response to interferon-gamma | 69/8552 | 118/18723 | 3.44e-03 | 1.41e-02 | 69 |
GO:00343411 | Liver | HCC | response to interferon-gamma | 82/7958 | 141/18723 | 1.25e-04 | 1.03e-03 | 82 |
GO:00713461 | Liver | HCC | cellular response to interferon-gamma | 70/7958 | 118/18723 | 1.66e-04 | 1.32e-03 | 70 |
GO:00343417 | Oral cavity | OSCC | response to interferon-gamma | 81/7305 | 141/18723 | 6.77e-06 | 7.43e-05 | 81 |
GO:00713465 | Oral cavity | OSCC | cellular response to interferon-gamma | 65/7305 | 118/18723 | 2.83e-04 | 1.79e-03 | 65 |
GO:003434131 | Oral cavity | NEOLP | response to interferon-gamma | 36/2005 | 141/18723 | 5.06e-07 | 1.52e-05 | 36 |
GO:007134631 | Oral cavity | NEOLP | cellular response to interferon-gamma | 27/2005 | 118/18723 | 1.03e-04 | 1.24e-03 | 27 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa0462112 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa0462132 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa046218 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa0462113 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa046216 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
hsa046217 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GBP4 | SNV | Missense_Mutation | c.524N>A | p.Pro175His | p.P175H | Q96PP9 | protein_coding | tolerated(0.13) | benign(0.181) | TCGA-05-4415-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
GBP4 | SNV | Missense_Mutation | novel | c.1867N>A | p.Pro623Thr | p.P623T | Q96PP9 | protein_coding | deleterious(0.02) | benign(0.025) | TCGA-05-5425-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | gefitinib | PD |
GBP4 | SNV | Missense_Mutation | rs375773007 | c.182N>C | p.Leu61Pro | p.L61P | Q96PP9 | protein_coding | tolerated(0.05) | benign(0.315) | TCGA-44-7671-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
GBP4 | SNV | Missense_Mutation | c.878C>G | p.Thr293Ser | p.T293S | Q96PP9 | protein_coding | tolerated(0.08) | benign(0.095) | TCGA-44-A47G-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GBP4 | SNV | Missense_Mutation | c.1808A>G | p.Glu603Gly | p.E603G | Q96PP9 | protein_coding | tolerated(0.07) | benign(0) | TCGA-49-6767-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GBP4 | SNV | Missense_Mutation | novel | c.1628N>A | p.Ala543Asp | p.A543D | Q96PP9 | protein_coding | tolerated(0.52) | benign(0.049) | TCGA-49-AAR4-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxol | PD |
GBP4 | SNV | Missense_Mutation | c.157G>T | p.Val53Leu | p.V53L | Q96PP9 | protein_coding | tolerated(0.12) | possibly_damaging(0.453) | TCGA-50-5049-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
GBP4 | SNV | Missense_Mutation | c.570N>A | p.Asp190Glu | p.D190E | Q96PP9 | protein_coding | deleterious(0.02) | possibly_damaging(0.674) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
GBP4 | SNV | Missense_Mutation | c.986N>T | p.Ala329Val | p.A329V | Q96PP9 | protein_coding | deleterious(0.03) | benign(0.388) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD | |
GBP4 | SNV | Missense_Mutation | novel | c.546C>A | p.Ser182Arg | p.S182R | Q96PP9 | protein_coding | deleterious(0.04) | benign(0.176) | TCGA-53-A4EZ-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |